Afatinib is active in osteosarcoma in osteosarcoma cell lines.

ABSTRACT:

Purpose

Osteosarcoma is the most common bone tumor, mainly affecting adolescents and young adults, and metastatic disease has poor outcomes with a dismal overall survival. Currently, chemotherapy is the standard of care with limited results, finding that new therapies could improve these outcomes. Preclinical and clinical studies have suggested a possible important role of ErbB pathway aberrations in osteosarcoma etiology. The present study shows the effect of afatinib, an irreversible ErbB family blocker in osteosarcoma cell lines.

Methods

Within a panel of human osteosarcoma cell lines, we addressed cell viability assay using afatinib at increasing concentrations. Motility was measured in wound-healing assays and invasion capacity was assessed in Transwell chamber assays.

SUBMITTER: Cruz-Ramos M 

PROVIDER: S-EPMC11804738 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature